title: The role of intraoperative heparin in cyclosporine treated cadaveric renal transplant recipients.
abstract: OBJECTIVE
  We analyze the effect of intraoperative heparin in cadaveric renal transplantation.
  
  
  METHODS
  We examined the records of 100 consecutive cadaveric transplant recipients who received 5,000 units of heparin at the time of vascular clamping (group 1), and compared the incidence of graft thrombosis and postoperative hemorrhagic complications to 100 consecutive cadaveric transplant recipients who did not receive heparin (group 2). The groups were similar in terms of donor age, sex, number of transplant recipients, sensitization, multiple vessels, delayed graft function and human leukocyte antigen mismatch. All patients received cyclosporine based triple therapy immunosuppression. All explanted grafts were examined histologically to rule out hyperacute rejection.
  
  
  RESULTS
  There was no statistical difference between the 2 groups. The overall incidence of graft thrombosis was 5% (6% in group 1 and 4% in group 2). There was a greater need for blood transfusion in group 1, with 25 patients requiring transfusion postoperatively versus 14 in group 2.
  
  
  CONCLUSIONS
  Intraoperative heparin did not reduce the incidence of graft thrombosis in this retrospective study. It did increase the postoperative blood transfusion requirements. As a result of this analysis, we have abandoned its use.
authors.affiliation: Department of Transplantation, Beaumont Hospital, Dublin, Ireland.
authors.forename: P
authors.initials: P
authors.lastname: Mohan
authors.forename: D M
authors.initials: DM
authors.lastname: Murphy
authors.forename: A
authors.initials: A
authors.lastname: Counihan
authors.forename: P
authors.initials: P
authors.lastname: Cunningham
authors.forename: D P
authors.initials: DP
authors.lastname: Hickey
mesh_terms: D000328:Adult; D000925:Anticoagulants / Q000627:therapeutic use*; D002648:Child; D016572:Cyclosporine / Q000009:adverse effects*; D005260:Female; D006493:Heparin / Q000627:therapeutic use*; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D015994:Incidence; D007430:Intraoperative Care; D016030:Kidney Transplantation; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000139:chemically induced / Q000453:epidemiology / Q000517:prevention & control*; D019106:Postoperative Hemorrhage / Q000139:chemically induced / Q000453:epidemiology / Q000517:prevention & control*; D012077:Renal Artery; D012082:Renal Veins; D013927:Thrombosis / Q000139:chemically induced / Q000453:epidemiology / Q000517:prevention & control*
chemical_list: D000925:Anticoagulants; D007166:Immunosuppressive Agents; D016572:Cyclosporine; D006493:Heparin